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Biomarkers that assess treatment response for patients with the autoimmune disorder,
myasthenia gravis (MG), have not been evaluated to a significant extent. We hypothesized
the pro-inflammatory cytokine, osteopontin (OPN), may be associated with variability of
response to glucocorticoids (GCs) in patients with MG. A cohort of 250 MG patients
treated with standardized protocol of GCs was recruited, and plasma OPN and polymorphisms of its gene, secreted phosphoprotein 1 (SPP1), were evaluated. Mean OPN
levels were higher in patients compared to healthy controls. Carriers of rs11728697*T
allele (allele definition: one of two or more alternative forms of a gene) were more frequent
in the poorly GC responsive group compared to the GC responsive group indicating an
association of rs11728697*T allele with GC non-responsiveness. One risk haplotype
(AGTACT) was identified associated with GC non-responsiveness compared with GC
responsive MG group. Genetic variations of SPP1 were found associated with the
response to GC among MG patients.
Keywords: myasthenia gravis, glucocorticoid, osteopontin, secreted phosphoprotein 1, quantitative myasthenia
gravis score

INTRODUCTION
Myasthenia gravis (MG) is a chronic autoimmune disorder caused by antibodies directed against
postsynaptic proteins, primarily the skeletal muscle nicotinic acetylcholine receptor (AChR). Oral
glucocorticoids (GCs) are the primary therapy (1, 2), but response rates to GCs are highly variable
among studies ranging from 5 to 30% (3–7). No clinical or biological markers exist that predict GC
responsiveness. Genetic polymorphisms have been identified that are associated with therapeutic
response to GCs in other autoimmune and inflammatory conditions (8), and we recently identified
Abbreviations: AChR, acetylcholine receptor; GC, glucocorticoid; ELISA, enzyme-linked immunosorbent assay; eQTLs,
expression quantitative trait loci; IVIG, intravenous immunoglobulin; LD, linkage disequilibrium; MG, myasthenia gravis;
OPN, osteopontin; PE, plasma exchange; QMGS, quantitative MG score; SNP, single nucleotide polymorphism; SPP1, secreted
phosphoprotein 1.
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a single nucleotide polymorphism (SNP) in the GC receptor
gene as an independent factor associated with short-term GC
responsiveness among patients with MG (9).
Osteopontin (OPN) is a pro-inflammatory cytokine, and
increased circulating levels have been associated with inflammatory muscle diseases and muscular dystrophy (10–13) as well
as the onset and progression of Crohn’s disease, myocarditis,
uveitis, idiopathic retroperitoneal fibrosis, and rheumatoid
arthritis (14–16). Furthermore, SPP1 gene polymorphisms have
been identified as being associated with GC responsiveness in
boys with Duchenne muscular dystrophy (13); however, a larger
validation study published after we began our work did not
confirm the association (17). We hypothesized that plasma OPN
may be a marker of treatment responsiveness and that genetic
variations (polymorphisms) in the secreted phosphoprotein 1
(SPP1) gene, which encodes OPN, are associated with differences
in GC responsiveness of patients with MG.
We assessed the relationship among clinical characteristics
and plasma OPN level of MG patients. Further, we evaluated
the relationship between SNPs of SPP1 gene and response to a
standardized 3-month GC treatment protocol with prospectively
collected outcome data. As our primary outcome assessment, we
used the quantitative MG score (QMGS), which is a validated
scale and was recommended by the MG Foundation of America
as the primary clinical outcome measure for clinical trials (18).
Several studies using the QMGS have shown that a change of 3 or
more points to be clinically meaningful (19–21).

Figure 1 | Enrollment profile. GC, glucocorticoid; IVIg, intravenous
immune globulin; SNP, single nucleotide polymorphism.

Table 1 | Comparison of the demographic and clinical characteristics of
patients between responsive and non-responsive patients with MG.
Variables

Study Population

We assessed the same cohort as in our separate association study
of GR gene polymorphisms and response to GCs (9). Three
hundred forty-two consecutively identified MG patients who
had not received immunosuppressive agents were recruited
and followed from Beijing Friendship Hospital, Capital Medical
University, and Affiliated Hospital of Qingdao University. The
diagnosis of MG was based on a typical clinical history of variable weakness involving ocular, bulbar, limb, or a combination
of muscle groups. Fatigable weakness was evident on physical
examination. Alternative diagnoses, such as central nervous
system disorders, myopathies, and motor neuron disorders were
excluded. A positive result in at least one of three was required:
(1) increased serum level of anti-acetylcholine receptor antibody
(AChRAb); (2) decremental response to low frequency repetitive
nerve stimulation; or (3) positive response to the neostigmine
test. Muscle specific kinase patients were excluded.
Fifty-two patients were excluded because of a contraindication to GC therapy or refusal to receive GC treatment. The GC
treatment was initiated with 0.75–1 mg/kg/day of prednisone or
equivalent methylprednisolone. The dosage of GCs was tapered
gradually when definite improvement was appreciated or was
maintained for 3 months. Patients who had received plasma
exchange, intravenous immunoglobulin or immunosuppressants during the study period were excluded. Patients who were
excluded for other causes are described in Figure 1. DNA samples
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Non-responsive p Value
(n = 19)

44.08 ± 16.38

42.74 ± 19.39

87
144

9
10

176
55

14
10

62
161

4
14

160
71

12
7

203
28

15
4

Disease duration before usage of GCs
Within 6 months
159
After 6 months
72
QMGS before treatment (median,
6
months)

9
10
7

Age of onset (years)
Gender
Male
Female
Thymoma
Absence
Presence
Anti-AChR antibody
Negative
Positive
Involved muscles at disease onset
Ocular muscle
Generalized muscle
Thymectomy
No
Yes

SUBJECTS AND METHODS

Responsive
(n = 231)

0.734
0.403

0.056

0.786

0.581

0.280

0.055
0.992

MG, myasthenia gravis; AChR, acetylcholine receptor; GC, glucocorticoid; QMGS,
quantitative myasthenia gravis score.

from seven patients were depleted from use in our previous
study (9). Two hundred fifty patient samples underwent SPP1
genotyping. A subset of 74 MG patients and 50 healthy controls
underwent evaluation for plasma for OPN levels. Patients were
stratified into subgroups by gender, age of onset (22), clinical
presentation at disease onset, AChRAb status, presence of thymoma, disease duration before treatment, and QMGS before
treatment (Table 1). Patients were followed monthly for 3 months
after treatment initiation and QMGS determined by a physician
trained in its performance (18). The control group consisted of
474 healthy individuals age-matched to the study population and
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Inhibition rate (%) = 100 × (test sample absorbance/negative
control absorbance).

seen during the study period at each participating institution.
All study participants were northern Han Chinese and nonconsanguineous. Change of QMGS was used as a primary efficacy
measurement. Improvement of 3 or greater points of the QMGS
or a QMGS becoming 0 identified a patient as being responsive
to GCs (21, 23). The study was approved by ethical committees
of the hospitals, and all participants provided written informed
consent.

SNP Selection and Genotyping

Twelve SNPs (variations in single base pairs in a DNA sequence)
were selected based on previous reports and information from
NCBI dbSNP and HapMap database [CHB database, HapMap
phase version 3, release 27 (2009, February)], in an attempt to
cover the majority of the SPP1 gene region by linkage disequilibrium (LD). Among the 12 SNPs, 1 tag SNP (rs2853749) was
selected using the HapMap database with the software as previously described, and 11 SNPs (rs2728127, rs2853744, rs11730582,
rs11439060, rs11728697, rs6840362, rs4754, rs1126616, rs4660,
rs1126772, and rs9138) were previously reported (25–33).
Ten of these have functional potential (rs2728127, rs2853744,
rs11730582, rs11439060 in the 5′ near gene; rs11728697, rs4754,
rs1126616, rs4660 in coding region; rs1126772, rs9138 in
3′-untranslated region). One SNP has been previously investigated (rs6840362), which showed a significant difference allele
distribution in European American patients with SLE (30). The
location and function of the SNPs are shown in Table 2.

Enzyme-Linked Immunosorbent
Assay (ELISA)

Blood samples were collected in ethylenediaminetetraacetic acid
from patients prior to the initiation of GC or any other immunotherapy. Plasma was isolated and stored at −80°C until evaluation.
The concentration of OPN was determined by the quantitative
sandwich ELISA using the Quantikine kit (R&D Systems,
Minneapolis, MN, USA). Antibodies against AChR (AChRAb)
was detected by using ELISA kit (RSR Limited, Cardiff, UK)
(24). The testing was performed according to the instructions
of the kit. The results were expressed as inhibition rate of AChR
binding, calculated according to the formula in the instructions:

Table 2 | Twelve SNPs in healthy control, GC responsive, and GC non-responsive groups.
SNP (major/minor)

Function

Genetic
models

Controlc (n = 474)

rs2728127

5′ near

ALLELIC

584/364

A/G

Gene

GENO
DOM
REC

169/246/59
169/305
415/59

rs2853744

5′ near

ALLELIC

578/370

G/T

Gene

GENO
DOM
REC

168/242/64
168/306
410/64

rs11730582

5′ near

ALLELIC

613/335

T/C

Gene

GENO
DOM
REC

202/209/63
202/272
411/63

rs11439060

5′ near

ALLELIC

579/369

–/G

Gene

GENO
DOM
REC

169/241/64
169/305
410/64

rs2853749

Intron 1

C/T

rs11728697

Intron 3

C/T

rs6840362

Intron 3

C/T

rs4754

Exon 6

ALLELIC

579/369

GENO
DOM
REC

168/243/63
168/306
411/63

ALLELIC

556/392

GENO
DOM
REC

161/234/79
161/313
395/79

ALLELIC

909/39

GENO
DOM
REC
ALLELIC

Responsivec
(n = 231)

Non-responsivec
(n = 19)

HWE‡

0.41

290/170

26/12

88/114/28
88/142
202/28

9/8/2
9/10
17/2

290/170

26/12

88/114/28
88/142
202/28

9/8/2
9/10
17/2

310/152

25/13

104/102/25
104/127
206/25

6/13/0
6/13
19/0

288/174

26/12

88/112/31
88/143
200/31

9/8/2
9/10
17/2

285/173

26/12

85/115/29
85/144
200/29

9/8/2
9/10
17/2

275/187

19/19

83/109/39
83/148
192/39

2/15/2
2/17
17/2

447/15

36/2

435/39/0
435/39
474/0

216/15/0
216/15
231/0

17/2/0
17/2
19/0

703/245

335/127

29/9

0.12

0.48

0.15

0.1

0.78

1

0.55

p
Valuea

ORb (95% CI)

0.508

0.787 (0.387–1.601)

0.74
0.44
0.83

0.69 (0.27–1.76)
0.85 (0.19–3.87)

0.508

0.787 (0.387–1.601)

0.74
0.44
0.83

0.69 (0.27–1.76)
0.85 (0.19–3.87)

0.701

1.146 (0.571–2.301)

0.035
0.25
0.232

1.77 (0.65–4.83)
0.92 (0.88–0.95)

0.456

0.764 (0.376–1.553)

0.73
0.43
0.71

0.68 (0.27–1.75)
0.76 (0.17–3.45)

0.448

0.760 (0.374–1.546)

0.68
0.38
0.78

0.66 (0.26–1.68)
0.81 (0.18–3.70)

0.252

1.471 (0.758–2.852)

0.018*
0.014*
0.45

4.77 (1.07–21.14)
0.58 (0.13–2.61)

0.378

1.656 (0.364–7.524)

0.53
0.63
NA

1.69 (0.36–8.03)
NA

0.612

0.819 (0.377–1.777)
(Continued )
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TABLE 2 | Continued
SNP (major/minor)

Function

C/T

rs1126616

Exon 7

T/C

rs4660

Exon 7

G/A

rs1126772

3′ UTR

A/G

rs9138

3′ UTR

Genetic
models

Controlc (n = 474)

GENO
DOM
REC

263/177/34
263/211
440/34

ALLELIC

703/245

GENO
DOM
REC

263/177/34
263/211
440/34

ALLELIC

948/0

GENO
DOM
REC

948/0/0
948/0
948/0

ALLELIC

685/263

GENO
DOM
REC

251/183/40
251/223
434/40

ALLELIC

702/246

GENO
DOM
REC

263/176/35
263/211
439/35

Responsivec
(n = 231)

Non-responsivec
(n = 19)

119/97/15
119/112
216/15

11/7/1
11/8
18/1

335/127

29/9

120/95/16
120/111
215/16

11/7/1
11/8
18/1

480/0

20/0

240/0/0
240/0
240/0

10/0/0
10/0
10/0

340/122

29/9

125/90/16
125/106
215/16

10/9/0
10/9
19/0

334/128

29/9

119/96/16
119/112
215/16

11/7/1
11/8
18/1

HWE‡

0.55

p
Valuea
0.86
0.59
0.83

0.77 (0.30–1.99)
0.80 (0.10–6.41)

0.612

0.819 (0.377–1.777)

0.87
0.62
0.77

0.79 (0.31–2.03)
0.75 (0.09–5.96)

NA

NA

NA
NA
NA

NA
NA

NA

0.42

0.47

ORb (95% CI)

0.714

0.865 (0.398–1.879)

0.24
0.9
0.619

1.06 (0.42–2.71)
0.92 (0.88–0.95)

0.593

0.81 (0.373–1.758)

0.86
0.59
0.77

0.77 (0.30–1.99)
0.75 (0.09–5.96)

p Value for Hardy–Weinberg equilibrium test among healthy controls.
Comparison between GC responsive MG with GC non-responsive MG.
c
Major homozygotes/heterozygotes/minor homozygotes.
ALLELIC, allelic test; GENO, genotypic test; DOM, dominant gene action test; REC, recessive gene action test; HWE, Hardy–Weinberg equilibrium;
NA, not applicable; GC, glucocorticoids; MG, myasthenia gravis; SNP, single nucleotide polymorphism.
The significant results are highlighted in bold. *p < 0.05.
‡

a,b

Single nucleotide polymorphism genotyping was performed
using a custom-designed SNPscanTM Kit (Genesky Biotechnologies
Inc., Shanghai, China). For quality assurance, 3.87% (28/724)
of the total samples were randomly repeated. Concordance for
duplicate samples was 100% for all assays.

that are inherited together. Haplotype frequencies were estimated
with Partition–Ligation–Combination–Subdivision Expectation
Maximization algorithm implemented in SHEsis software.

Functional Annotation and Expression
Quantitative Trait Locus (eQTL) Analysis

Statistical Analysis

Functional annotations of SNPs were investigated using
RegulomeDB, a database which provides assessment of whether
SNPs are located in known or predicted regulatory elements,
including regions of DNase I hypersensitivity, binding sites for
transcription factors (TFs), and promoter regions that regulate
transcription (34).
With the aim of exploring the molecular basis of the observed
associations, eQTLs analysis was performed by using published
cell-specific eQTL dataset (35).

Statistical analysis was performed with SPSS Statistics 13 (SPSS
Corporation, Chicago, IL, USA), SHEsis software (Bio-X Life
Science Research Center, Shanghai, China), Haploview 4.2 software, and GraphPad Prism 5 (GraphPad Software, Inc., La Jolla,
CA, USA). A two-side comparison with p < 0.05 was considered
statistically significant. The database, constructed using SQL
server, contains data pertaining to the SNPs, clinical features and
treatment, and clinical follow-up of patients.
The normality of the data was tested using the method of
Kolmogorov and Smirnov. Continuous variables were presented as
mean ± SD or median, 25th and 75th percentiles; categorical variables were presented as a percentage. Differences between groups
were analyzed with independent sampled t test or the Mann–
Whitney U-test for continuous variables and by chi-square test or
Fisher exact test for categorical variables. The association between
the GC efficacy and MG phenotype and SPP1 genotypes was examined by multivariate regression analysis. In this pilot study, we did
not make a correction for multiple comparisons. The Haploview 4.2
software was used to calculate pairwise LD of SNPs and construct
haplotype blocks. Haplotypes are defined as genetic variations
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RESULTS
Patient Characteristics

The study cohort consisted of 250 patients of which 154 (61.6%)
were women (Table 1). The onset age ranged from 15 to 80 years,
mean 43.98 ± 16.59 years. The disease duration prior to GC
therapy ranged from 0.2 to 48 months with a median duration
of 4 months (interquartile range of 2–11 months). Among 474
healthy controls, 238 were men, and 236 are women with an age
range of 14–78 and median age of 45 years.
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OPN Concentrations in MG Patients
and Healthy Controls

Response to GCs

Quantitative MG score ranged from 1 to 35 (median QMGS was 6,
interquartile ranged from 4 to 11) at study onset, and after 3 months
of treatment, a significant reduction in QMGS was observed ranging from 0 to 29 points (median QMGS was 1, interquartile ranged
from 0 to 3, p < 0.0001). The change in QMGS ranged from −2 to
18 (median QMGS was 5, interquartile ranged from 3 to 8).
Two hundred thirty-one patients (92.4%) were considered GC
responsive, and 19 (7.6%) were considered GC non-responsive.
Clinical characteristics of the patients are summarized in Table 1.
No differences were found between a poor response to GC
therapy with age of onset, gender, presence of thymoma, AChR
antibody status, muscle group involvement at disease onset,
thymectomy, disease duration before GC treatment, or QMGS
before treatment (p = 0.73, 0.41, 0.78, 0.79, 0.59, 0.28, 0.06, and
0.99, respectively) (Table 1).

Prior to initiation of immunotherapy, mean OPN plasma levels
were greater among MG patients (68.33 ± 43.03 ng/ml) compared
to healthy controls (50.19 ± 38.74 ng/ml; p = 0.013; Figure 2). We
performed a subgroup analysis of the patients with the highest
OPN levels (mean + 2 SD of controls; 127.67 ng/ml in the study),
which identified 8 patients, and compared them to the remaining
66 patients (Figure 3). We found that the MG patients with the
highest levels of OPN had lower percentage of positive AChRAb
(37.5 vs 85.94%, p = 0.006, Figure 3C). No difference in onset age,
gender, presence of thymoma, involved muscle group at disease
onset, duration before GCs treatment, QMGS at the sample
collection, and change of QMGS after 3 months GC treatment
(p = 0.667, 0.227, 0.641, 1.00, 1.00, 0.373, 0.606, respectively,
Figures 3A,B,D–H) was found between the two subgroups.

Association between SPP1 Gene Variation
and Response to GC

The success rates of genotyping the 12 SNPs among MG patients
and healthy controls were greater than 99.7%. None of the participants had the rs4660 polymorphism. The genotyping data of
12 SNPs of the healthy controls did not deviate from the Hardy–
Weinberg equilibrium (HWE, p = 0.1–1, Table 2). General
characteristics of 12 SNPs in the SPP1 gene of patients are shown
in Table 2. The distribution of genotypes in the GC sensitive
and insensitive groups was consistent with the Hardy–Weinberg
equilibrium (Table 2).
The rs11728697 T carriers (C/T + T/T genotypes) were more
frequent in the GC non-responsive group compared to the GC
responsive group (89.5 vs 64.1%; dominant model: p = 0.014;
OR = 4.77, 95% CI = 1.07–21.14), indicating association with
a poor response to GCs. No statistically significant differences
were observed for the remaining SNPs (Table 2). No difference in

Figure 2 | Osteopontin (OPN) levels among myasthenia gravis (MG)
patients and healthy controls. Mean OPN levels were higher in MG
patients (68.33 ± 43.03 ng/ml) compared to healthy controls
(50.19 ± 38.74 ng/ml; p = 0.013).

Figure 3 | Clinical features of myasthenia gravis (MG) patients with the greatest osteopontin (OPN) levels. The MG patients with the highest levels of
OPN had lower percentage of positive acetylcholine receptor (AChR) antibody (37.5 vs 85.94%, p = 0.006, Figure 3C). No difference in age of disease onset,
gender, presence of thymoma, involved muscle at disease onset, duration before glucocorticoid (GC) treatment, quantitative MG score (QMGS) at the sample
collection, and change of QMGS after 3 months GC treatment (p = 0.667, 0.227, 0.641, 1.00, 1.00, 0.373, 0.606, respectively, Figures 3A,B,D–H).
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the frequency of the rs11728697 T carriers was observed between
MG patients and healthy control groups (66 vs 66%, dominant
model, p = 0.99).
The association between SPP1 gene variation and responses
to GCs was further examined by multivariate logistic regression
analysis, with GC non-response as the dependent variable, and
with onset age, gender, involved muscles at disease onset, AChRAb,
presence of thymoma, disease duration before GC treatment,
and rs11728697 as independent variables. The rs11728697 T
carrier was found as an independent factor for GC non-responsiveness (p = 0.019, OR = 4.76, 95% CI = 1.03–21.99).

second from rs4754 to rs9138 (rs4754, rs1126616, rs1126772,
and rs9138; D′ ranging from 0.99 to 1.0). A total of four common haplotypes were identified across the first block, ranging in
frequency from 35.5 to 7.3% in all patients (GTTGTC: 35.5%,
AGCACT: 32.6%, AGTACC: 21.5%, AGTACT: 7.3%). One risk
haplotype (AGTACT) in the first block was identified (OR = 2.61,
95% CI = 1.09–6.73, p = 0.041) in the GC non-responsive MG
group compared with GC responsive MG group (15.8 vs 6.5%)
(Table 3). Three common haplotypes were identified across
the second block, ranging in frequency from 46.4 to 27.0% in
total patient (CTAC: 46.4%, TCAA: 27.0%, CTGC: 26.2%). No
risk haplotype was found across the second block. There was
no difference of OPN concentration between MG patients with
rs11728697 CC (77.34 ± 54.36 ng/ml) and those with rs11728697
CT + TT (61.84 ± 31.68 ng/ml; p = 0.127) (Figure 5).

SPP1 Haplotypes and GC Efficacy
in MG Patients

The LD test among 12 SNPs in the SPP1 gene is shown in Figure 4.
According to Haploview, the haplotype block structure of the SPP1
gene consists of two blocks. The first block ranges from rs2728127
to rs11728697 (rs2728127, rs2853744, rs11730582, rs11439060,
rs2853749, and rs11728697; D′ ranging from 0.93 to 1.0), the

RegulomeDB Analysis of rs11728697

According to the functional annotation information from the
RegulomeDB scoring, rs11728697 was identified as score 1d

Figure 4 | Haplotype block of SPP1 variants. Generated by Haploview (version 4.2). Dark red, strong linkage disequilibrium (LD); light red, weak LD.

Table 3 | Haplotype analysis of the SPP1 gene variants between glucocorticoids responsive and non-responsive subjects.
ID

1
2
3
4

Haplotype

GTTGTC
AGCACT
AGTACC
AGTACT

Frequency
Responsive

Non-responsive

0.355
0.326
0.219
0.065

0.316
0.342
0.184
0.158

χ2

p

OR (95% CI)

0.414
0.003
0.372
4.185

0.520
0.955
0.542
0.041*

0.792 (0.389–1.613)
1.021 (0.507–2.053)
0.768 (0.328–1.797)
2.606 (1.009–6.729)

Haplotypes constructed by rs2728127, rs2853744, rs11730582, rs11439060, rs2853749, and rs11728697.
The significant results are highlighted in bold. *p < 0.05.
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gene of an immuno-modulating protein was associated with GC
responsiveness in MG.
There is no accepted definition of treatment response for MG
therapeutics, which is a limitation of our investigation. As more
precise clinical and biological definitions of treatment response
are identified, genetic and biomarker studies may identify more
robust associations. The QMGS is a validated scale and was
recommended by the MG Foundation of America Task Force as
the primary clinical outcome measure (19). Several studies have
indicated that an improvement of 3 or more points on the QMG
scale is clinically meaningful (19–21). Pascuzzi and colleagues
treated 116 patients with similar regimens of 60–80 mg daily of
prednisone and with prolonged follow-up, 5% were described as
unresponsive to treatment (3). Our result is consistent with the
findings of this investigation. Others have found higher rates of
limited treatment response using less strict definitions from ours.
However, their study had a longer observational length, which
would indicate that treatment failure may have been contaminated by patients developing GC complications. A retrospective
study over 2 years of observation found 13% of patients were
unchanged or worse, and in a long-term study of 104 patients, 13
percent had no improvement in MG manifestations with treatment (6, 7). Further, an observational study without a standardized treatment protocol found about one-third of patients have
significant disability despite 6 months of treatment, which usually
included prednisone (40).
We found that the mean plasma concentration of OPN was
significantly increased in MG patients compared with controls,
which is consistent with its role as a pro-inflammatory cytokine
and is consistent with its elevation in other autoimmune and
inflammatory diseases (38). We did not appreciate an association of OPN levels with any clinical parameters or genotypes of
this SNP. There are several potential explanations. Circulating
cytokine levels have disease-related and diurnal variations, which
may not have been accounted for by this study. The investigation
may not have been able to distinguish disease-specific variations
due to a lack of statistical power. From the present investigation
whether circulating OPN levels or mutations in SPP1 may be
predictive of treatment response cannot be determined. SPP1
expression is elevated in muscle of animals with passive transfer
MG (41). OPN has been found to be involved in progression of
endogenous autoreactive germinal centers leading to enhanced
antinuclear antibody production in an animal of lupus (42),
which points to the multiple mechanisms that are involved in
autoantibody production. No difference in the proportion of
rs11728697 T carrier was found in association with the plasma
level of OPN. This likely relates to several potential factors
impacting circulating levels of OPN, including other genetic
associations with GC response.
In summary, increased mean plasma levels of OPN are found
among MG patients, but these had no relationship to patient
demographics or treatment response. We found a mutation at
rs11728697 and two haplotypes in the SPP1 gene to be associated
with poor response to GC treatment among MG patients. In particular, subgroup analyses did not find associations with clinical
characteristics of patients, but conclusions are limited because
of small sample sizes. A larger validation study will be required

Figure 5 | Osteopontin (OPN) concentrations in subgroups with
rs11728697 genotypes. No difference in OPN concentrations was found
between rs11728697 CC (77.34 ± 54.36 ng/ml) and rs11728697 CT + TT
(61.84 ± 31.68 ng/ml).

(http://www.regulomedb.org/snp/chr4/88898940) with evidence
for eQTL, TF binding, a matched TF binding motif, and location
within DNase-sensitive site. rs11728697 is within the region of
the binding site of TF regulatory factor X 3 that was detected by
Chip-Seq analysis in K562 cell line (36). rs11728697 was found to
be linked with rs12502049 (D′ = 0.958 and R2 = 0.724), which was
identified as score 1f with evidence for mapping to a predicted TF
binding site and/or within a DNase I sensitivity peak and correlating with gene expression. rs12502049 is known to regulate the
expression of SPP1 gene that was detected by eQTL analysis in a
lymphoblastoid cell line (37).

DISCUSSION
We identified an SNP in the SPP1 gene (rs11728697), which was
associated a poor response to GC treatment among patients with
MG. One risk haplotype (AGTACT) containing a mutation at
this SNP was identified among the GC non-responsive patients
compared with the GC responsive patients. The carrier of the
variant does not differ between MG patients and the controls,
indicating the association of rs11728697 T with GC response is
not determined by its involvement in pathogenesis of MG but
associates with GC treatment response. Presently, there is no
evidence of a direct interaction between OPN and GC response
pathways; however, OPN influences T and B cell function,
which provides indirect pathways that could be associated with
GC treatment responsiveness (38). Further, rs11728697 is in a
location of the SPP1 gene that may bind transcriptional factors
offering a mechanism for GC effect.
Previous studies of genetic variations of response to GC
therapy in autoimmune or inflammatory disorders are limited.
Investigation of GC responsiveness in SLE identified SNP associations in the GC receptor gene (39). We also identified an SNP
in the GC receptor gene that was associated with a poor treatment
response among patients with MG (9). A study of Duchenne muscular dystrophy found an rs28357094 polymorphism, which lies
in the gene promoter of SPP1, to be associated with GC response.
In this study, we aimed to explore whether polymorphisms in the
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to confirm these observations. For MG and other autoimmune
disorders, it is critical to move toward identification of markers
that predict treatment response with the intent of providing
individual treatment (43).

statistical analysis. YM maintained the database and determined
the pathologic diagnosis for the study.
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